NewsBenzingaSeres Therapeutics presentará datos preclínicos que respaldan el desarrollo de SER-428, un LBP oral líquido en investigación para reducir el riesgo de infecciones del torrente sanguíneo en pacientes críticamente enfermos, en IDWeek 2026 Seres Therapeutics presentará datos preclínicos que respaldan el desarrollo de SER-428, un LBP oral líquido en investigación para reducir el riesgo de infecciones del torrente sanguíneo en pacientes críticamente enfermos, en IDWeek 2026 Benzinga 2026.10.15 11:07 (GMT+0) Open on Benzinga Other news argenx Q3 EPS $7.80 Misses $7.83 Estimate, Sales $1.751B Beat $1.664B Estimate Nokia Q3 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $5.931B Beat $5.800B Estimate Meta reaches deal with Zuckerberg: grants non-voting shares to address California wealth tax, in exchange for 8-year residency Advancements in DRAM, HBM and NAND Driving Technology Leadership in the AI Era eBay China launches large-scale personnel adjustment, with ratio possibly reaching 80% Kingstone: Less Reinsurance Means More Earnings And More Volatility (NASDAQ:KINS)
Meta reaches deal with Zuckerberg: grants non-voting shares to address California wealth tax, in exchange for 8-year residency
